Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 116

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 116
---
 condition could be materially and adversely affected by epidemics and other outbreaks of communicable diseases, including the COVID -19pandemic, and by the economic and operational disruptions caused by the attempts of governmental entities to contain or flatten the spread of the disease. Global health concerns relating to COVID -19have negatively affected the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty. The COVID -19pandemic created significant, widespread and unprecedented volatility, uncertainty, and economic instability, disrupting broad aspects of the global economy, capital markets, our operations, our workforce and our supply chain. Many of these effects continue to varying 35 degrees and further mutated variants and outbreaks globally or regionally continue to harm recovering consumer confidence and have led to renewed implementation of harsh preventative measures by local and regional governments and businesses. The level and nature of the disruption caused by a pandemic is unpredictable, may be cyclical and long -lastingand may vary from location to location. A pandemic could materially impact our business for an unknown period of time, including in the following ways: •reduced access for our sales team to potential customers; •a need to shut down or operate our Argentine Wet -Labat a minimum due to quarantine, disrupting our operations and product deliveries; •delays and/or cancellations of Rewell test kits and/or Heritas Diagnostics sample logistics, nutrigenetic coaching and/or medical geneticist appointments, and other operational procedures which may negatively affect orders for our products or services; •illness, quarantines, financial hardships, restrictions on travel and commerce, and supply chain disruptions, which may hinder our, and our suppliers’ and customers’, businesses and workforces; •periods of reduced demand from our diagnostic laboratory partners, which may cause us to suspend certain operations and/or services; and •abrupt changes to operating plans, which may seek to manage volatile conditions but may hinder our commercial and development activities. Any of the above occurrences could have an adverse impact on our business, financial condition, results of operations and growth prospects. Our operating results may fluctuate significantly and can be difficult to predict. Our operating results may be subject to significant fluctuations due to a variety of factors, including currency fluctuations, inflation, seasonal variations or non -seasonalevents, pricing of our tests, collection of payments from third -partyand other payers, success in marketing and selling our tests, research and development activities, negative publicity, customer and patient preferences, competitive conditions, and changes in overall spending levels in the life sciences industry. Our